Section 'Sub' Navigation:
Dr. Jennifer Le
Infectious Diseases and Pharmacokinetics
Jennifer Le, PharmD, MAS, BCPS-ID, FCCP, FCSHP
Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Research Summary: Infectious Diseases - Pediatrics
Dr. Jennifer Le’s primary research interests encompass the safe and effective use of antimicrobial agents, their pharmacokinetic and pharmacodynamic properties, and outcomes associated with resistant infections in neonatal and pediatric populations. As a board certified pharmacotherapy specialist with added qualifications in infectious diseases, Dr. Le maintains a clinical practice site at Miller Children's and Women's Hospital and Long Beach Memorial Hospital where she conducts most of her patient-oriented research.
Some of her current research projects include: pharmacokinetic-pharmacodynamic modeling of vancomycin/ampicillin/meropenem/ceftaroline in infants and children; nephrotoxicity associated with vancomycin in children; optimizing outcomes of Gram-negative infections with translational research; and complications associated with Staphylococcus aureus bacteremia in children.
B.S. in Biology (1995) UCLA; Pharm.D. (2000) UCSF; ASHP-accredited Residency in Pharmacy Practice (2001) Long Beach Memorial and Miller Children's Hospital; Board certification in pharmaceutical sciences with added qualification in infectious diseases (2007) (BCPS-ID); APhA-certified in pharmacy-based immunization delivery (2008); MAS in Clinical Research (2012).
Awards and Honors:
K23 Award from NIAID (2010- 2015); Fellow of ACCP (2011); New Investigator Award from ACCP (2007); Faculty Service of the Year Award at Western Univ. (2009); member of Rho Chi Honor Society; Fellow of CSHP (2013)
Editorial Board Member for new ACCP textbook in pediatric pharmacotherapy; Selected Member of Task Force for the Board of Pharmacy Specialties for Infectious Diseases; journal/book reviewer for Pediatr Infect Dis J, J of Antimicrob Chemother, Clin Therapeutics and PSAP- Infectious Diseases Book 9
- Intro to Clinical Pharmacokinetics (SPPS 212A)
- Digoxin Pharmacokinetics (SPPS 212B)
- Pharmacology of vancomycin and aminoglycosides (SPPS 249)
- Anticonvulsants Pharmacokinetics (SPPS 212C)
- Pediatric Infections (SPPS 246A&B)
- Pneumonia and Viral Infections (SPPS 246A&B)
- Clinical Pharmacokinetics of Vancomycin and Aminoglycosides (SPPS 246A&B)
Key Contributions to Pharmaceutical Sciences
- Effective use of antimicrobial medications in pediatric and adult hospitalized patients.
- Clinical research in antimicrobial medication utilization in the inpatient setting.
Selected Recent Publications (view more)
- Le et al. (2013). Time to initiation of antifungal therapy for neonatal candidiasis. Antimicrobial Agents and Chemotherapy 57:2550-55.
- Le et al. (2013). Enhanced, exposure-based vancomycin dosing in children by the area-under-the-curve. Pediatric Infectious Diseases Journal 32:e155- 63.
- Le et al. (2014). Accuracy of vancomycin monitoring in children using Bayesian estimation. Therapeutic Drug Monitoring 36:510-8.
- Le et al. (2015). Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. Journal of Pediatric Infectious Diseases Society (4:e109-16)
- Le et al. (2015) Bayesian estimation of vancomycin pharmacokinetics in obese children: matched case-control study. Clinical Therapeutics. 37:1340-51.
Potential Collaborative Programs with the Pharmaceutical Industry
- Identify opportunities for research programs surrounding optimal antimicrobial use and dosing in patients, especially children, with resistant infections
- Develop service interventions and novel practice models that will improve utilization of antimicrobial medications in hospitalized pediatric and adult patients
- Conduct pharmacokinetic-pharmacodynamic modeling of antimicrobial agents in pediatrics